Updated:
Tyra Biosciences
Tyra Biosciences engineers resistance-proof kinase inhibitors from Carlsbad, CA.
Tyra Biosciences
Tyra Biosciences was founded in 2018 by Todd Harris alongside chemist Robert Hudkins, with headquarters in Carlsbad, California. The company works at the intersection of structural biology and computational drug design. Its lead candidate, TYRA-300, is a selective FGFR3 inhibitor aimed at treating genetically defined cancers, particularly bladder cancer, while sparing other FGFR isoforms to reduce the side effects seen with pan-FGFR inhibitors. The firm's platform, called SNAP (Structure-based Nucleotide and Prodrug), relies on solving high-resolution crystal structures of target kinases to identify binding pockets unique to disease-causing variants. The thesis is simple: current kinase inhibitors hit too many healthy receptors, causing dose-limiting toxicities. Tyra's candidates lock onto single mutations. Beyond TYRA-300, the pipeline includes TYRA-200, a RET inhibitor designed to bypass on-target resistance mutations that emerge during existing RET-inhibitor treatments. In 2023, Tyra also disclosed a preclinical FGFR4 program for metabolic-associated steatohepatitis (MASH), extending the platform beyond oncology into liver disease. All programs remain fully owned by the company. Tyra raised approximately $204 million in its 2021 IPO on the Nasdaq Global Select Market under the ticker TYRA, and has since been followed by institutional biotech investors including RA Capital Management and Boxer Capital. As of the most recent public filings, Tyra employs a small team of drug-discovery scientists in San Diego County. In March 2024, the company presented updated Phase 1 data for TYRA-300 at the American Association for Cancer Research (AACR) annual meeting, showing early but durable tumor shrinkage in patients with metastatic urothelial carcinoma who had exhausted prior therapies — the first clinical proof of its isoform-selective thesis. What separates Tyra from the hundreds of preclinical oncology biotechs is its board-level commitment to a single-product lead marketed in sequence across histological subtypes. The Western-snapper approach — proving the compound in one orphan indication, then broadening the label — mirrors the commercial path of Loxo Oncology before its acquisition by Eli Lilly. Founders Harris and Hudkins retain significant operational control, and the firm's low-burn capital model disproportionately rewards survival: with no commercialization cost for at least five years, every dollar compounds toward the larger registrational trials.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Carlsbad
Corporate office
Carlsbad, CA, United States
Principals
Todd Harris
CEO and Co-Founder
Robert Hudkins
CTO and Co-Founder
Sector focus
Frequently asked questions
What is Tyra Biosciences' lead program, and what makes it different from existing kinase inhibitors?
The lead program is TYRA-300, a selective FGFR3 inhibitor initially targeting metastatic bladder cancer. Unlike older pan-FGFR drugs that hit all four FGFR isoforms, TYRA-300 binds exclusively to FGFR3. That selectivity is designed to spare healthy tissue and avoid the hyperphosphatemia and nail toxicity that limit dosing with earlier agents, potentially allowing everyone who harbors the mutation to stay on therapy longer and see deeper tumor responses.
How does Tyra's SNAP platform work?
SNAP stands for Structure-based Nucleotide and Prodrug. The team solves crystal structures of kinase targets at atomic resolution, identifies pockets unique to disease-driving mutations, and designs molecules that fit only those pockets. The platform also incorporates prodrug chemistry — modifying the molecule so it activates preferentially in the tumor microenvironment — which improves both selectivity and oral bioavailability.
Who runs investment decisions and the board at Tyra Biosciences?
Todd Harris serves as CEO and remains the lead decision-maker on capital allocation and pipeline prioritization. The board includes representatives from major institutional backers RA Capital Management and Boxer Capital, but Harris and co-founder Robert Hudkins control the operational science agenda. There is no external portfolio manager; Tyra is a single-program operating company, not a fund.
Is Tyra a single-family office investment vehicle or a biotech operating company?
Tyra is a publicly traded biotech operating company, listed on Nasdaq under the ticker TYRA since September 2021. It is not a family office, a venture fund, or a holding company. Every dollar raised from public investors or institutional crossover rounds goes directly into the company's own single pipeline.
What is Tyra's known posture on partnering or co-development?
As of the latest public disclosures, all programs are wholly owned with no revenue-sharing or co-development partnerships announced. The company has stated an explicit preference for retaining global rights through at least the first regulatory approval, which is consistent with a long-duration public-market drug-development model rather than a venture-capital exit strategy.
How is Tyra Bio linked to the old wave of kinase inhibitors?
Tyra's founding thesis is explicitly a reaction to the limitations of multi-targeted kinase inhibitors from the 2000s and 2010s. Co-founder Robert Hudkins previously led kinase chemistry at Cephalon, where he worked on early-generation pan-kinase programs. Tyra was built to solve the toxicity and resistance problems those older drugs left on the table, not repeat them.
What cancers does Tyra target beyond bladder cancer?
TYRA-300 is being studied across all solid tumors that carry FGFR3 mutations or fusions, which include a subset of cholangiocarcinomas, gliomas, and head and neck cancers. Separately, TYRA-200 targets RET-altered cancers including non-small cell lung cancer and medullary thyroid cancer. A preclinical FGFR4 program targets MASH and hepatocellular carcinoma.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: